Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14288444 | 0.98 | TBXA2R (0.46) | CYP19A1SIGMAR1FAAHCYP3A4CYP2D6 | |
| SCHEMBL904927 | 0.94 | CYP19A1 (0.47) | CYP19A1SIGMAR1FAAHCYP3A4CYP2D6 | |
| SCHEMBL21023395 | 0.86 | ACHE (0.48) | CYP19A1FAAHCYP3A4CYP2D6TSHR | |
| SCHEMBL7714102 | 0.85 | CYP19A1 (0.44) | CYP19A1FAAHCYP3A4CYP2D6TSHR | |
| SCHEMBL19231987 | 0.83 | NR1I2 (0.47) | SLC6A3 | |
| SCHEMBL20633856 | 0.82 | NR1I2 (0.50) | — | |
| SCHEMBL22649183 | 0.82 | HTR7 (0.39) | SLC6A3 | |
| SCHEMBL21346544 | 0.82 | NR1I2 (0.50) | — | |
| SCHEMBL8102586 | 0.82 | AOC3 (0.50) | SIGMAR1MEN1KMT2A | |
| SCHEMBL8217828 | 0.82 | HTR7 (0.39) | SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107078352-A | Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery using same | 三菱化学株式会社 | 2017-08-18 | — | — | CN | disclosed |
| US-20120214798-A1 | Novel Ethanediamone Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| EP-1153921-A2 | Cyclic ureas and analogues useful as retroviral protease inhibitors | Dupont Pharmaceuticals Company (US) | 2001-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214798-A1 | Novel Ethanediamone Hepcidine Antagonists | HAMP, SLC40A1, FTH1 | CYP19A1 784/4885SIGMAR1 1369/4885FAAH 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.